Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Wegovy
Biotech
Novo plots ph. 3 trials for next-gen obesity asset amycretin
The Danish pharma is moving forward with both subcutaneous and oral versions of amycretin, a GLP-1 and amylin receptor agonist.
Gabrielle Masson
Jun 13, 2025 10:35am
Fierce Pharma
Novo's longtime CEO Lars Fruergaard Jørgensen to step down
May 16, 2025 9:41am
'All hands on deck' at Lilly as peers target obesity market
Aug 8, 2024 1:40pm
Viking to charge quickly into phase 3 with obesity med
Jul 25, 2024 9:19am
The most valuable R&D projects? You guessed it: obesity
Jul 11, 2024 5:00am
Novo Nordisk Foundation inks R&D pact for global health issues
May 6, 2024 10:59am
